OB-GYN Joins COLA’s Board of Directors
COLA announces the American Medical Association’s (AMA) appointment of Madelyn E. Butler, MD, to COLA’s Board of Directors.
Read MorePosted by Chris Wolski | Nov 22, 2022 | Company News |
COLA announces the American Medical Association’s (AMA) appointment of Madelyn E. Butler, MD, to COLA’s Board of Directors.
Read MorePosted by Chris Wolski | Nov 22, 2022 | Unknown Origin & Other Cancer Types |
Positive liver cancer detection data demonstrates the promise of Delfi Diagnostics’ liquid biopsy platform in a new tumor type.
Read MorePosted by Chris Wolski | Nov 21, 2022 | Controls, Molecular Diagnostics |
ZeptoMetrix, an Antylia Scientific company, launches the NATtrol Bacteriophage MS2 quantitative stock: NATMS2-STQ.
Read MorePosted by Chris Wolski | Nov 21, 2022 | Melanoma |
Roche has announced the launch of the PRAME Antibody to identify PRAME protein expression with suspected melanoma.
Read MorePosted by Andy Lundin | Nov 18, 2022 | Unknown Origin & Other Cancer Types |
A new AI blood testing tech called DELFI successfully detected more than 80% of liver cancer cases in a new study.
Read More